JADE3

Across TCGA pan-cancer cohorts, JADE3 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated JADE3 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher JADE3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated JADE3 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, LUAD, and PDAC are the cancer types where JADE3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.996	0.666	.009	10	view →
LUAD	DFS	Quartile	III,IV	0.215	0.854	.010	7	view →
PDAC	DFS	Median	All	0.907	0.526	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

JADE3–LSCC (OS)

Open the LSCC breakdown →